About us

SUCCIPRO is a spin-off company from IISPV and URV which aims to exploit the succinate-metabolic-inflammatory axis to create novel, first-in class therapeutics for inflammatory and metabolic diseases

MISSION

To leverage on cutting-edge unique scientific knowledge on succinate biology to develop novel therapeutic agents that reduce excess succinate levels, promoting a healthy microbiome, reducing intestinal and systemic inflammation, and preventing fibrosis. SUCCIPRO plans to advance its lead program to early-stage clinical development for Inflammatory Bowel Disease (IBD), as well as to explore additional indications of the technology in other diseases that present with elevated levels of succinate, such as MAFLD, T2D or cancer.

VISION

Succinate-modulation therapies will provide novel safe and effective therapeutic alternatives for patients living with chronic illnesses with a strong chronic inflammatory component, having a bold positive impact on the long-term health and quality of life of the overall population.

The Project

OUR STORY

SUCCIPRO is a project born from solid science on succinate pathophysiology from the DIAMET Research group, located at IISPV . SUCCIPRO is exclusively focused on succinate-modulating therapies.

PIONEERS

We are pioneers in the discovery and development of novel pharmaceuticals based on our unrivaled understanding of succinate biology and its role at the crossroad of inflammation and metabolism.

OUR TECHNOLOGY

We are using our knowledge, expertise and unique proprietary tools to generate a pipeline of pre-clinical candidates with a focus on inflammatory and metabolic diseases.

Science

SUCCINATE BIOLOGY
Succinate is a normal metabolite produced both by human cells but also by gut microbiome.

Succinate is much more than a mere fueling source, since it has many additional roles derived from both intracellular but also extracellular actions through its receptor SUCNR1. This pleiotropy allows succinate to have many different and sometimes differing functions both in health and disease.
Overall, in many different contexts succinate acts as a pro-inflammatory stimulus regulating local stress, tissue damage and immune response and is also a well-known oncometabolite. Importantly, succinate is elevated in pathological situations such as IBD (Crohn’s Disease), cancer, type-2 diabetes, obesity, hypertension, MAFLD or ischemic heart disease, among others.

WHY SUCCINATE?
We have demonstrated that intestinal succinate is a relevant source of circulating succinate, thus setting the stage for the development of our proprietary gut-restricted succinate-decreasing therapies to treat inflammatory and metabolic diseases, being Inflammatory Bowel Disease our first clinical indication.

List of Publications

Our Technology

Succinate is elevated in many pathological situations with a metabolic and/or an inflammatory component. Building on the breakthrough science from DIAMET research team, we are currently developing drugs able to reduce succinate to improve metabolism and reduce inflammation.

We have a diversified pipeline of biological proprietary succinate-modulating compounds with different Target Product Profiles.

Our first asset is a first-in-class, gut- restricted, monitorable, succinate-modulating therapy able to decrease intestinal and systemic succinate, improve inflammation and metabolism and prevent fibrosis that has Inflammatory Bowel Disease as a Primary Indication.

Founders

Isabel Huber, PhD, MBA

CEO & Co-founder

Pharmacist holding a PhD in Biochemistry from the University of Barcelona and an MBA from the Barcelona Biotechnology with more than 10 years of expertise in preclinical research

View Profile

Joan Vendrell, MD

CMO & Co-founder

Clinical coordinator of the DIAMET research group. Head of Endocrinology at the Joan XXIII University Hospital and full professor at the Universitat Rovira i Virgili.

View Profile